Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension

NCT02283853 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02283853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2014
Completion date
July 8, 2025
Enrollment
156 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis